MetaVia Inc. announced new late-breaking data from its obesity and metabolic disease portfolio presented at the American Diabetes Association’s (ADA) 2026 Scientific Sessions. The highlight was interim Phase 1 results for its obesity drug candidate, DA-1726, which demonstrated significant, progressive weight loss in a higher-dose cohort. The company also presented positive preclinical data for its drug vanoglipel, supporting its potential in combination therapies.
Key Details
- DA-1726 Efficacy: In a Phase 1 study, the 48 mg cohort of obesity candidate DA-1726 demonstrated a mean body weight reduction of 9.1% at Day 54, with continued reductions and no evidence of plateau.
- Safety & Tolerability: The treatment was generally well tolerated, with predominantly mild-to-moderate transient gastrointestinal adverse events and no serious adverse events reported.
- Vanoglipel Preclinical Data: Positive preclinical studies showed vanoglipel, in combination with other therapies, produced synergistic effects on weight loss and hepatoprotection in mouse models of MASH and type 2 diabetes.